Pipeline one：HJ-550 introduces targeted design into platinum-based drugs for the first time, significantly outperforming current first-line chemotherapy drugs (such as traditional platinum drugs, paclitaxel, and adriamycin) in treating highly lethal cancers like lung cancer, gastric cancer, and triple-negative breast cancer. Pipeline two：HJ-462 features protein kinase inhibitors with ingenious molecular designs that avoid defects in drug metabolism within the body, resulting in excellent safety and remarkable efficacy (achieving 100% tumor regression in liver cancer, gastric cancer, and lung cancer models caused by MET amplification, effectively curing these conditions).